| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating | 
|---|
																	
																	
																	
																	On September 23, 2025, Seres Therapeutics, Inc. (the "Company") announced actions to reduce operating costs in order to...
																	Following recent constructive FDA feedback, Seres anticipates finalizing SER-155 Phase 2 study protocol for the prevention of b...